Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
The War of Attrition: Why Intco’s Price War Will Fail, and Why Hartalega Will Survive
In the current market, many investors are panicking over Hartalega's (HARTA) upcoming Q2 profit collapse. They see the ASP (Average Selling Price) dropping from US19, and they assume the glove recovery is dead.
But if you look beneath the surface—through the lens of forensic accounting and the Munger/Buffett mental model—a very different picture emerges.
This is not a story of industry failure. It is a story of a "War of Attrition" between two giants. And the math proves that Hartalega is the one that will walk away victorious.
The "Illogical" Strategy of Intco
The global glove industry is currently an Oligopoly trapped in a brutal price war. China’s Intco Medical is violating the fundamental Law of Supply. Even though ASPs have crashed to US$17–19 per 1,000 pieces—well below their manufacturing cost—they are cranking their factories to full capacity and flooding Europe and Asia with cheap gloves.
Why would they do this?
To bankrupt their competitors and seize market share.
But where is the money coming from?
Intco doesn't have the massive cash pile that Hartalega has. They are funding this suicidal price war through state-backed, ultra-low-interest loans from Chinese banks, and by burning through the capital they raised during the COVID boom. They are using borrowed money to sell gloves at a loss.
Why Intco Will Lose (The Munger Inversion)
If we invert the question, it becomes clear: How long can Intco bleed cash?
Intco is betting that Hartalega will blink first and cut production. They are wrong.
Hartalega’s Fortress:
· Cash Pile: RM 1.1 Billion (Zero net debt).
· Lowest Cost Structure: Plant 9’s automation has reduced headcount by 27.3% and slashed manufacturing costs to ~US$11.50 per 1,000 pieces.
· US Market Moat: With 100%+ US tariffs on Chinese gloves, Hartalega owns a protected market where they can still generate healthy margins.
In an Oligopoly price war, the winner is not the one who sells the cheapest—it is the one who can bleed the longest. Hartalega can bleed for 3–4 years. Intco cannot survive 2 years burning borrowed cash.
The Q2 "Crash": Why You Shouldn't Panic
Many investors are terrified of Hartalega's Q2 FY2027 results (due in November). The math shows profits will drop from RM70M back down to ~RM20M–RM25M.
This is not a sign of failure. This is a working capital cycle.
In Q1, Hartalega strategically hoarded RM465M worth of raw materials to secure supply before gas tariffs and NBR prices spiked further. In Q2, they will be forced to consume that expensive inventory while selling into a lower ASP environment. This creates a temporary "cost mismatch."
The silver lining: By Q3, the expensive inventory will be depleted, and Hartalega will return to buying cheaper raw materials. The margin recovery will be swift.
The Key Takeaway: Focus on Cash, Not Paper Profits
Over the last 4 quarters, Hartalega generated RM 792 Million in Operating Cash Flow against RM 160 Million in Net Profit.
An unethical CEO might massage depreciation numbers to inflate paper profits, but you cannot massage the Cash Flow Statement. The cash either went out the door to buy machines, or it stayed in the bank. Hartalega's RM 1.1 Billion cash pile is real, and it is growing.
My Strategy: Survive the Bleed, Ride the Consolidation
I am holding my shares. Not because I believe in a "glove boom," but because I believe in the math.
1. Break-Even Analysis: In the current market (ASP US$19–20), Hartalega is still operating 80% above its break-even point. They are not at risk of bankruptcy.
2. The Game of Chicken: The current price war cannot last forever. When Intco runs out of cash and is forced to raise prices, Hartalega will be the last man standing, with the lowest cost structure and the cleanest balance sheet.
3. The Exit: When that consolidation occurs, the market will re-rate Hartalega violently to the upside.
The market is pricing Hartalega as if Intco will win. But the math proves Intco will run out of money before Hartalega runs out of patience.
Disclaimer: This is a personal analysis based on publicly available financial data and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.
With Hartalega (HARTA) hovering around RM1.00 after its stellar Q1 FY2027 results, many investors are focusing on the volatility of Average Selling Prices (ASP) and the threat of Chinese competition. However, I believe the market is missing the bigger picture.
My conviction in this company is not based on the "war-driven ASP spike." It is based on Management’s capital allocation discipline and their structural cost advantage. Here is why I believe Hartalega remains the only relevant Malaysian glove maker for the long haul:
1. The "Efficiency Gap" vs. Chinese Competitors
We often hear that Chinese players (like Intco) will "undercut everyone." However, look at the hard numbers: Hartalega’s Plant 9 (NGC 1.5) reduces manufacturing costs by 16% and lowers headcount by 8% using AI vision systems and automated stripping.
The Chinese business model of "薄利多销" (small margins, high volume) works in a bull market, but it is unsustainable when raw material (NBR) costs spike and ASPs drop. When you sell at US$18-20 per 1,000 pieces, who survives? The manufacturer with the lowest cost per unit. Hartalega is consistently pushing that cost floor lower, while their competitors are bleeding cash to keep their massive factories running.
2. Capital Allocation: The Top Glove Contrast
If you want to see the difference between a "survivor" and a "casualty," look at the history of capital allocation. During the pandemic boom, many competitors (specifically Top Glove) misallocated billions by aggressively buying back shares at the absolute peak of the stock price (draining cash) and over-expanding.
Hartalega’s management did the opposite. They hoarded RM1.14 Billion in cash, maintained practically zero net debt, and only initiated share buybacks when the stock was trading below RM0.90 (as seen in their recent buyback records). They did not chase the meme-stock hype. They protected their balance sheet. This is the hallmark of a rational, long-term management team.
3. The US and European "Certification" Moat
Price is only one factor in the US and European medical supply chains. Quality and regulatory compliance are the true barriers to entry. It takes years of stringent audits (FDA 510k, CE Marking, ISO 13485) and proven reliability to become a trusted supplier to major US hospital networks.
When Chinese manufacturers redirect excess capacity to non-US markets to survive, they are fighting a price war in regions that will trade quality for cost. However, the $60 billion+ US/EU medical market will still pay a premium for reliability. Hartalega’s automation ensures consistency, and their long-standing track record ensures they remain relevant in these high-value markets.
4. The "Oil Tanker" Risk (The Cash Cushion)
The biggest risk to Hartalega today is the gas tariff hike and the NBR cost mismatch in Q2. However, even with a projected 65% drop in next quarter’s profits, Hartalega is not at risk of bankruptcy. They have RM1.14 Billion in cash, no net debt, and a 60% dividend policy. They can weather a 2-3 year price war while the weaker players (both local and Chinese) burn through their cash.
Conclusion:
The market is treating Hartalega like a "trading play" based on the Iran war. I treat it as a "Cigar Butt" with a generational capital allocator at the helm. I do not expect the stock to return to RM4.00. However, I am confident that over the next 3-5 years, Plant 9’s cost efficiencies and management’s disciplined capital deployment will allow Hartalega to steadily grow its EPS back to pre-war normalized levels.
When everyone is fighting over a shrinking pie, I'm betting on the one with the sharpest knife and the deepest pockets.
This is a clear positive for shareholders(short-to-medium term).
· Why it’s good: It proves that PPB’s core business is actively winning new work. A 241-day contract (with a 30-day extension option) guarantees steady revenue and utilization for that vessel well into 2027.
· What’s missing: The contract value is not disclosed (due to confidentiality). You don’t know the exact profit margin. However, because they are providing "crew and equipment" for 24-hour service, this is typically a high-margin, recurring revenue stream.
· Key date: The contract starts 9 July 2026 (just days away), so the cash flow benefit will begin almost immediately.
2. The Share Capital Reduction (High Court Order Granted)
This is a neutral-to-positive accounting exercise (long-term impact).
· What happened: The High Court approved the reduction on 30 July 2026. The company now just needs to lodge the sealed order with SSM (Companies Commission) for it to take effect.
· Is it cash or a book adjustment? it is strictly a book adjustment. There is no mention of cash payout.
· Why the company does this: Perdana likely uses this to wipe out accumulated losses on their balance sheet. By clearing past losses, their retained earnings account becomes clean.
· Why it matters to shareholders :
· No immediate cash — your wallet is unaffected.
· Future dividends: With accumulated losses wiped out, PPB will be legally able to pay dividends from future profits. This paves the way for potential cash returns to shareholders in the years ahead.
· Clean balance sheet: It makes the company look healthier to investors and banks, which helps them secure future loans for things like those new AHTS vessels they are building.
Let’s use the Munger/Buffett "Invert" principle to dissect,
On Cost in China is way lower than Malaysia." (Reality: FALSE)
This is the biggest myth being spread right now.
· The Data: In the Kenanga report, it explicitly stated: "Through automation, Malaysian glove makers have reduced production costs by ~20%, significantly narrowing the cost gap with Chinese manufacturers."
· Why it matters: China's Intco does not have a massive cost advantage anymore. Hartalega's Plant 9 automation has brought their cost per 1,000 pieces down to ~RM16.80. Chinese factories have rising labor costs and environmental compliance costs. The cost difference today is razor-thin.
On Supply way more than demand." (Reality: TRUE for Medical Gloves)
· Global capacity is ~530B pieces; demand is ~373B pieces. There is massive oversupply.
· However, this is a problem for weak players. Hartalega is not a weak player. In a price war, the strongest survivor wins. Hartalega has zero net debt and RM1.14 billion in cash. When the oversupply forces small, debt-ridden factories to close, Hartalega will pick up their market share at pennies on the dollar.
On Wasting time on this industry... spend time on other MOATs.
This is where you are partially right.
You are right that medical gloves do not have a permanent, 30-year moat. The moat is only temporary (cost automation).
However, if you look at the UOB Riverstone report, that proves that Cleanroom / Semiconductor gloves DO have a permanent moat.
· Why? Because it takes 20+ years of trust and stringent quality certifications to supply an AI/Semiconductor chip factory. Chinese competitors cannot easily break into that market.
The market is always right about the supply-demand math in the short term. But the market is frequently wrong about the long-term survivability of the best-in-class operator.
The person who bought at RM20.00 during the COVID mania was not an investor; they were a gambler. They bought a commodity stock at a 100x PE ratio during a once-in-a-century pandemic, thinking the mania would last forever.
Charlie Munger’s view on this:
"The first rule of an investment is: Don't lose money. The second rule is: Never forget rule number one."
The person who bought at RM20 has already broken both rules. The market does not care about their loss. The share price is not sitting at RM0.965 because of them; it is sitting there because of industry oversupply. The "pity" you feel is an emotional trap designed to make you fearful.
1. The Immediate Impact: The "NBR Shortage" is BACK
· In March, traffic collapsed to near-zero.
· It briefly recovered in early July (the spike we see).
· But in late July, The traffic have dropped again to almost zero.
What this triggers:
Nitrile Butadiene Rubber (NBR)—the key raw material for nitrile gloves—is heavily dependent on crude oil and petrochemical shipments passing through this strait.
If the strait closes again, NBR supply will tighten massively. We saw this in March/April, which pushed Average Selling Prices (ASPs) from US28 per 1,000 pieces.
The market will immediately anticipate that NBR prices will spike, forcing glove makers to raise ASPs again to protect margins.
2. The "Irrational" Market Reaction Must Watch For
Here is the psychological irony of the market:
· Yesterday's News: The unconfirmed rumor about Trump "ending" the deal sent a false signal that war was escalating. It caused a brief, confused rally.
· Today's Chart reported by The Financial Times: This is actual, verified data (Lloyd's List Intelligence) showing ships are not moving. This is a concrete supply shock.
Potential scenario: When the mainstream financial media picks up this FT chart (within the next 24 hours), retail and institutional traders will start buying glove stocks again.
However, do not get euphoric. The market learned a hard lesson in June: Geopolitical disruptions are temporary. As soon as the strait reopens, ASPs will crash again.
3. The Strategic Impact on August QR
This chart is a massive tailwind for the August quarterly report (April–June 2026).
· The April–June quarter captured the first Hormuz closure (March).
· Now, this July disruption means that the next quarter (July–Sept) might also see elevated ASPs.
· The takeaway: Hartalega is going to report explosive profits for August. And if the strait remains blocked through August/September, they will report another strong quarter in November.
4. The ONE Risk to Watch (The "Temporary" Trap)
The FT chart also shows a brief recovery in early July. If this current closure is just a 2-week blip (e.g., ships waiting for a new negotiation), ASPs might only stay high for a month.
· If the strait reopens fully by August, the stock price could collapse right after the August QR is released, because the market will look forward to Q3/Q4 and see ASPs falling again.
Summary: This FT chart proves the NBR supply disruption is real and ongoing, not a one-time event.
